We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

DexCom DXCM3.23%increase; green up pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...

HCPs see CGM as the 'standard of care': Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not. 96% of ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company. It focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems.

Dexcom delivered 8% quarterly revenue growth, but several one-time expenses, including tax adjustments and intellectual property litigation, drove earnings down 40%. Why it matters: Fourth-quarter ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.6 ...

Two excellent examples are DexCom (NASDAQ: DXCM) and Vertex Pharmaceuticals (NASDAQ: VRTX). EDINBURGH, Scotland & SAN DIEGO, March 19, 2025--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response. The diabetes devices ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...